Autologous point‐of‐care cellular therapies variably induce equine mesenchymal stem cell migration, proliferation and cytokine expression

Abstract

The specific clinical indications for these products may differ to include administration as a sole treatment modality prior to MSCs injection for intrinsic cell and cytokine activity (i.e. SVF) or administration concurrently with MSCs to activate MSCs for treatment of chronic lesions (i.e. CBMNs).